← Back to Search

VM202 for Peripheral Arterial Disease (HI-PAD Trial)

Phase 2
Waitlist Available
Led By Mary McDermott, MD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to three-month follow-up
Awards & highlights

HI-PAD Trial Summary

This trial is testing whether VM202 may improve walking ability in people with PAD.

Eligible Conditions
  • Peripheral Arterial Disease

HI-PAD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to six-month follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to six-month follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Calf muscle biopsy biochemical measures
Calf muscle perfusion
Maximal and pain-free treadmill walking time
+2 more
Other outcome measures
Six-minute walk distance

HI-PAD Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: VM202Active Control1 Intervention
Participants will receive injections of VM202 (4 mgs) in calf skeletal muscle every 14 days for a total of four treatment days.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive injections of placebo in calf skeletal muscle every 14 days for a total of four treatment days.

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,574 Previous Clinical Trials
909,614 Total Patients Enrolled
24 Trials studying Peripheral Arterial Disease
4,383 Patients Enrolled for Peripheral Arterial Disease
National Institute on Aging (NIA)NIH
1,653 Previous Clinical Trials
28,004,936 Total Patients Enrolled
20 Trials studying Peripheral Arterial Disease
16,556 Patients Enrolled for Peripheral Arterial Disease
Helixmith Co., Ltd.Industry Sponsor
19 Previous Clinical Trials
1,594 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential risks accompany the use of VM202?

"As this is a Phase 2 clinical trial, and thus no efficacy data has been established yet, the safety of VM202 was estimated to be level 2."

Answered by AI

Are there any openings available for participants in this medical trial?

"Affirmative. Clinicaltrials.gov confirms that this research study, which was initially created on January 1st 2018, is actively recruiting participants. 39 people need to be enlisted from one medical facility."

Answered by AI

How many participants have the capacity to join this research project?

"Affirmative, according to the data posted on clinicaltrials.gov this study is actively seeking participants with enlistment commencing as of January 1st 2018 and last edited April 21st 2022. 39 patients are needed from one site for successful completion of the trial."

Answered by AI
~5 spots leftby Mar 2025